Exelixis, Inc.

Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor Xl147 (SAR245408) in Combination with Erlotinib at the AACR-NCI-EORTC Conference [Press Release]
Business Wire | 4 days 14 hours 32 minutes ago
Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors. XL147 is a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy. The pathway also has been ...

Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor XL147 (SAR245408) in Combination with Paclitaxel and Carboplatin at the AACR-NCI-EORTC Conference [Press Release]
Business Wire | 5 days 14 hours 32 minutes ago
Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with paclitaxel and carboplatin in patients with advanced solid tumors. XL147 is a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy. Upregulation of PI3K signali...

Exelixis Announces Third Quarter 2009 Financial Results [Press Release]
Business Wire | 24 days 11 hours 52 minutes ago
Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the third quarter ended September 30, 2009.

Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer [Press Release]
Business Wire | 30 days 9 hours 32 minutes ago
Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today reported updated phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

Thirteen Abstracts Featuring Exelixis Compounds Accepted for Presentation at the 2009 AACR-NCI-EORTC International Conference [Press Release]
Business Wire | 18 days 21 hours 2 minutes ago
Exelixis, Inc. (Nasdaq: EXEL) announced today that thirteen abstracts related to the company’s development candidates have been accepted for presentation at the 2009 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held November 15-19 in Boston. Interim data from ongoing phase 1 clinical trials of XL147 and XL765 will be reported in four poster presentations. Exelixis is co-developing XL147 and XL765 in collaboration with sanofi-aventis. Cli...

Ligand Updates License Agreement with Exelixis [Press Release]
Business Wire | 20 days 18 hours 32 minutes ago
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has amended its license agreement with Exelixis, Inc. (NASDAQ: EXEL) as a result of which Ligand is now entitled to receive royalties on net sales of future products from a mineralocorticoid receptor program and a one-time $75,000 payment for providing access to certain patent rights. Also, as a result of Ligand’s settlement with Salk last year, the amendment eliminated certain minimum annual royalties that may have been payable by Exelixis.

Exelixis Announces October 29 Webcast of Third Quarter 2009 Financial Results Conference Call [Press Release]
Business Wire | 39 days 22 hours 2 minutes ago
Exelixis, Inc. (Nasdaq:EXEL) will release its third quarter 2009 financial results on Thursday, October 29, 2009 after the markets close. The announcement will be followed by a live webcast at 5:00 p.m. EDT/ 2:00 p.m. PDT, in which Exelixis management will discuss the results and provide a general business update. The webcast may be accessed in the Event Calendar page under Investors at www.exelixis.com.

Reportlinker Adds Small Molecule Kinase Inhibitors Report [Press Release]
PRNewswire | 75 days 17 hours 30 minutes ago
...players worldwide such as Amgen, Inc., Asahi Kasei Pharma Corporation...Squibb Company, Celgene Corporation, Exelixis, Inc., F. Hoffmann-La Roche, Ltd...Pharmaceutical Co, Ltd., Genentech, Inc., GlaxoSmithKline plc., KAI Pharmaceuticals...

BVGH Announces New Board Chair [Press Release]
PRNewswire | 68 days 19 hours ago
... In addition to serving on the board of BVGH, Feldbaum serves on the Board of Directors of Actelion, LTD and Exelixis, Inc., both biotechnology companies, and the Biotechnology Institute. He is president emeritus of the Biotechnology...